SAN DIEGO, CA - April 16, 2025 (NEWMEDIAWIRE) - Quantumzyme Corp. (OTC: QTZM), a biotechnology company leveraging computational enzyme engineering, is providing insight into the company’s enzymatic design capabilities and current areas of research-particularly in the field of sustainable pharmaceutical manufacturing.
As part of its green chemistry initiatives, Quantumzyme has been evaluating enzyme-based methods to reduce the environmental footprint of common small molecule drug production. One area of focus has been the development of an enzyme-driven approach to ibuprofen synthesis. Ibuprofen, a widely used anti-inflammatory and pain relief medication, is typically produced through multi-step chemical processes that involve hazardous reagents and generate significant chemical waste.
“At Quantumzyme, we’re exploring how computationally designed enzymes can be used to reimagine traditional chemical processes,” stated Naveen Kulkarni, CEO of Quantumzyme. “While our work on ibuprofen synthesis continues to evolve, it illustrates the potential of enzyme catalysis to reduce complexity and environmental impact in pharmaceutical manufacturing.”
The company’s enzyme discovery efforts center on its proprietary in silico platform, which integrates structural modeling, molecular docking, and virtual screening to identify enzymes with high specificity and stability for industrially relevant reactions. In the case of ibuprofen, Quantumzyme’s team screened 22 candidate enzymes and identified a promising variant- bcPADH from Burkholderia cenocepacia- capable of converting a key intermediate (ibuprofen aldehyde) into the final active pharmaceutical ingredient under lab conditions.
By using bacterial systems to express and optimize this enzyme, the company has been able to achieve high conversion efficiency and purity, under safer, low-energy conditions. Importantly, this method avoids the use of harsh substances such as hydrofluoric acid, carbon monoxide, and pyrophoric metals commonly found in traditional synthesis routes.
While Quantumzyme’s current research around ibuprofen is one application, the platform is being developed to support a wide range of use cases across pharmaceuticals, specialty chemicals, agrochemicals, and biofuels. The company’s strategy focuses on applying green chemistry principles to reduce hazardous inputs, minimize waste, and improve process efficiency across sectors.
“This is about more than one molecule,” added Kulkarni. “We’re building a platform that can be applied broadly- wherever sustainable, precise biocatalysis can offer value over conventional chemistry.”
Quantumzyme continues to optimize its enzyme systems and evaluate potential commercial pathways for future deployment. We are presently assessing scale-up feasibility and industry integration for our enzyme-enabled solutions.
For the most current information and updates, please visit our website at www.quantumzymecorp.com.
About Quantumzyme Corp.
Quantumzyme Corp. is a pioneering biotransformation company revolutionizing chemical processes through sustainable, enzyme-based solutions. Specializing in green chemistry, it harnesses quantum mechanics, molecular modeling, AI-driven simulations, and computational enzyme engineering to design high-performance biocatalysts that enhance efficiency, reduce waste, and minimize environmental impact. By integrating computational modeling with wet-lab validation, Quantumzyme delivers scalable, cost-effective biocatalysis solutions that improve industrial sustainability. Offering end-to-end enzyme development services- from discovery and engineering to process optimization and scale-up—Quantumzyme empowers its partners to adopt greener, more efficient production methods. Committed to sustainability and innovation, the company envisions a future where biotechnology drives global solutions for climate change, pollution, and resource efficiency, making eco-friendly biocatalysis the industry standard.
Disclaimer
The information contained in this press release is provided by Quantumzyme Corp. (“Quantumzyme”) for general informational purposes only. This release may include forward-looking statements that reflect Quantumzyme’s current expectations, estimates, projections, and assumptions about future events, business performance, market conditions, or technological developments. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. Forward-looking statements are based on management’s beliefs and assumptions as of the date of this press release and are subject to change without notice.
Quantumzyme makes no representations or warranties, express or implied, regarding the accuracy, completeness, or reliability of the information contained herein. The company undertakes no obligation to publicly update or revise any forward-looking statements as a result of new information, future developments, or changes in expectations, except as required by applicable law. Past performance should not be taken as an indicator of future results, and readers should not place undue reliance on any projections or expectations presented in this release.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor does it provide financial, investment, or legal advice. Any references to market trends, scientific advancements, or industry insights are provided for contextual purposes only and should not be interpreted as endorsements, guarantees, or definitive predictions of future developments. Readers and investors are encouraged to conduct their own due diligence and seek independent professional advice before making any investment or business decisions related to Quantumzyme or its affiliates.
Media Contact:
Naveen Kulkarni
Chief Executive Officer
Quantumzyme Corp.
15656 Bernardo Center Drive, Suite 801
San Diego, CA 92127
Phone: +1 (858) 203-0312
Email: info@quantumzymecorp.com
Website: www.quantumzymecorp.com
View the original release on www.newmediawire.com
